# Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

> **NCT00269412** · PHASE2 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 525 (estimated)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT00269412
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-08
- **Final completion:** 2008-09
- **Target enrollment:** 525 (ESTIMATED)
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269412, "Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00269412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*